Back to Search
Start Over
Technology evaluation: ABT-510, Abbott.
- Source :
-
Current opinion in molecular therapeutics [Curr Opin Mol Ther] 2004 Aug; Vol. 6 (4), pp. 451-7. - Publication Year :
- 2004
-
Abstract
- ABT-510 is a small peptide thrombospondin-1 mimetic angiogenesis inhibitor under development by Abbott Laboratories for the potential treatment of solid tumors. ABT-510 is undergoing phase II clinical trials.
- Subjects :
- Amino Acid Sequence
Angiogenesis Inhibitors adverse effects
Angiogenesis Inhibitors genetics
Angiogenesis Inhibitors therapeutic use
Animals
Antineoplastic Agents adverse effects
Antineoplastic Agents therapeutic use
Clinical Trials, Phase II as Topic
Humans
Mice
Oligopeptides adverse effects
Oligopeptides genetics
Oligopeptides therapeutic use
Thrombospondin 1 chemistry
Angiogenesis Inhibitors metabolism
Antineoplastic Agents metabolism
Oligopeptides metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1464-8431
- Volume :
- 6
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Current opinion in molecular therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- 15468604